Key Takeaways in Renal Cell Carcinoma from Abstract 4512
The panel examines the key findings from abstract 4512 and evaluates its potential impact on the current treatment paradigm for renal cell carcinoma.
Video Player is loading.
EP: 1.Overview of RCC Histology and Incidence Rates
EP: 2.CLEAR Trial Updates From ASCO 2024
EP: 3.TKIs, Disease Progression and Subsequent Therapy in RCC
EP: 4.ASCO 2024 Updates: nccRCC + Chromophobe RCC
EP: 5.PAPMET Phase II Trial Advances Cancer Treatment Landscape
EP: 6.Chromophobe Renal Cell Carcinoma: Key Features and Diagnosis
EP: 7.Examining Predictors of Chromophobe Renal Cell Carcinoma Recurrence
EP: 8.ASCO 2024: Abstract 4512 Overview
Now Viewing
EP: 9.Key Takeaways in Renal Cell Carcinoma from Abstract 4512
EP: 10.Phase II and KEYNOTE B-61: Comparative Analysis of Cancer Trials
Recent Videos
The Treatment Landscape For Advanced EGFR-Mutant NSCLC
Clinical Case: EGFR-Mutant (Exon 19 del) Advanced NSCLC
COMMANDS and ELEMENT-MDS Trials: Long-Term Analysis, Survival, Duration of Response, and Hemoglobin Levels
Early vs Late Onset of ESA in LR-MDS: Results From Phase 3 EPO-PRETAR Trial
Strategies for Monitoring and Managing T-DXd-Related Adverse Effects
The Evolving Role of T-DXd in HER2+ Metastatic Breast Cancer
Ocular AE Management in Ovarian Cancer: Coordination Between Oncology and Eye Care Teams
CEPHEUS Trial: Efficacy in Transplant-Ineligible Patients
CAR T Monitoring Strategies: Balancing Patient Safety With Quality of Life Considerations
CEPHEUS Trial: MRD Negativity
Related Content
